Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Asztalos, Bela F; Collins, Dorothea; Horvath, Katalin V; Bloomfield, Hanna E; Robins, Sander J; Schaefer, Ernst J

Asztalos, Bela F; Collins, Dorothea; Horvath, Katalin V; Bloomfield, Hanna E; Robins, Sander J; Schaefer, Ernst J.

Affiliation

Asztalos BF; Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. bela.asztalos@tufts.edu

Metabolism ; 57(1): 77-83, 2008 Jan.

Article in En | MEDLINE | ID: mdl-18078862

Subject(s)

Cardiovascular Diseases/epidemiology; Coronary Disease/epidemiology; Gemfibrozil/therapeutic use; Hypolipidemic Agents/therapeutic use; Lipoproteins, HDL/blood; Coronary Disease/prevention & control; Humans; Hypertension/epidemiology; Lipids/blood; Lipoproteins, HDL/classification; Male; Placebos; Proportional Hazards Models; Prospective Studies; Risk Reduction Behavior; United States; United States Department of Veterans Affairs

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Gemfibrozil / Coronary Disease / Lipoproteins, HDL / Hypolipidemic Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Country/Region as subject: America do norte Language: En Journal: Metabolism Year: 2008 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google